First Time Loading...

Homology Medicines Inc
NASDAQ:FIXX

Watchlist Manager
Homology Medicines Inc Logo
Homology Medicines Inc
NASDAQ:FIXX
Watchlist
Price: 0.9347 USD 1 714.95%
Updated: Apr 26, 2024

Intrinsic Value

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. [ Read More ]

The intrinsic value of one FIXX stock under the Base Case scenario is 0.1693 USD. Compared to the current market price of 0.9347 USD, Homology Medicines Inc is Overvalued by 82%.

Key Points:
FIXX Intrinsic Value
Base Case
0.1693 USD
Overvaluation 82%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Homology Medicines Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling FIXX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Homology Medicines Inc

Provide an overview of the primary business activities
of Homology Medicines Inc.

What unique competitive advantages
does Homology Medicines Inc hold over its rivals?

What risks and challenges
does Homology Medicines Inc face in the near future?

Has there been any significant insider trading activity
in Homology Medicines Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Homology Medicines Inc.

Provide P/S
for Homology Medicines Inc.

Provide P/E
for Homology Medicines Inc.

Provide P/OCF
for Homology Medicines Inc.

Provide P/FCFE
for Homology Medicines Inc.

Provide P/B
for Homology Medicines Inc.

Provide EV/S
for Homology Medicines Inc.

Provide EV/GP
for Homology Medicines Inc.

Provide EV/EBITDA
for Homology Medicines Inc.

Provide EV/EBIT
for Homology Medicines Inc.

Provide EV/OCF
for Homology Medicines Inc.

Provide EV/FCFF
for Homology Medicines Inc.

Provide EV/IC
for Homology Medicines Inc.

Show me price targets
for Homology Medicines Inc made by professional analysts.

What are the Revenue projections
for Homology Medicines Inc?

How accurate were the past Revenue estimates
for Homology Medicines Inc?

What are the Net Income projections
for Homology Medicines Inc?

How accurate were the past Net Income estimates
for Homology Medicines Inc?

What are the EPS projections
for Homology Medicines Inc?

How accurate were the past EPS estimates
for Homology Medicines Inc?

What are the EBIT projections
for Homology Medicines Inc?

How accurate were the past EBIT estimates
for Homology Medicines Inc?

Compare the revenue forecasts
for Homology Medicines Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Homology Medicines Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Homology Medicines Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Homology Medicines Inc compared to its peers.

Compare the P/E ratios
of Homology Medicines Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Homology Medicines Inc with its peers.

Analyze the financial leverage
of Homology Medicines Inc compared to its main competitors.

Show all profitability ratios
for Homology Medicines Inc.

Provide ROE
for Homology Medicines Inc.

Provide ROA
for Homology Medicines Inc.

Provide ROIC
for Homology Medicines Inc.

Provide ROCE
for Homology Medicines Inc.

Provide Gross Margin
for Homology Medicines Inc.

Provide Operating Margin
for Homology Medicines Inc.

Provide Net Margin
for Homology Medicines Inc.

Provide FCF Margin
for Homology Medicines Inc.

Show all solvency ratios
for Homology Medicines Inc.

Provide D/E Ratio
for Homology Medicines Inc.

Provide D/A Ratio
for Homology Medicines Inc.

Provide Interest Coverage Ratio
for Homology Medicines Inc.

Provide Altman Z-Score Ratio
for Homology Medicines Inc.

Provide Quick Ratio
for Homology Medicines Inc.

Provide Current Ratio
for Homology Medicines Inc.

Provide Cash Ratio
for Homology Medicines Inc.

What is the historical Revenue growth
over the last 5 years for Homology Medicines Inc?

What is the historical Net Income growth
over the last 5 years for Homology Medicines Inc?

What is the current Free Cash Flow
of Homology Medicines Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Homology Medicines Inc.

Financials

Balance Sheet Decomposition
Homology Medicines Inc

Current Assets 83.9m
Cash & Short-Term Investments 82.7m
Other Current Assets 1.3m
Non-Current Assets 650k
PP&E 650k
Current Liabilities 11.6m
Accounts Payable 3.2m
Accrued Liabilities 8.3m
Efficiency

Earnings Waterfall
Homology Medicines Inc

Revenue
1.2m USD
Operating Expenses
-93.3m USD
Operating Income
-92.1m USD
Other Expenses
-20.9m USD
Net Income
-113m USD

Free Cash Flow Analysis
Homology Medicines Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

FIXX Profitability Score
Profitability Due Diligence

Homology Medicines Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

9/100
Profitability
Score

Homology Medicines Inc's profitability score is 9/100. The higher the profitability score, the more profitable the company is.

FIXX Solvency Score
Solvency Due Diligence

Homology Medicines Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Homology Medicines Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FIXX Price Targets Summary
Homology Medicines Inc

Wall Street analysts forecast FIXX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FIXX is 1.5 USD .

Lowest
Price Target
Not Available
Average
Price Target
1.5 USD
60% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

FIXX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

FIXX Price
Homology Medicines Inc

1M 1M
-
6M 6M
-9%
1Y 1Y
-3%
3Y 3Y
-86%
5Y 5Y
-96%
10Y 10Y
-95%
Annual Price Range
0.9347
52w Low
0.5309
52w High
1.43
Price Metrics
Average Annual Return -46.68%
Standard Deviation of Annual Returns 28.37%
Max Drawdown -98%
Shares Statistics
Market Capitalization 54.2m USD
Shares Outstanding 58 133 500
Percentage of Shares Shorted 0.04%

FIXX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Homology Medicines Inc Logo
Homology Medicines Inc

Country

United States of America

Industry

Biotechnology

Market Cap

54.2m USD

Dividend Yield

0%

Description

Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the design and development of treatments to address rare diseases at the genetic level. The company is headquartered in Bedford, Massachusetts and currently employs 224 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Contact

MASSACHUSETTS
Bedford
1 Patriots Park
+17813017277.0
https://www.homologymedicines.com/

IPO

2018-03-28

Employees

224

Officers

President & COO
Dr. Paul Alloway J.D., Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Saswati Chatterjee Ph.D.
VP of Finance, Corporate Controller & Treasurer
Mr. Charles Michaud Jr., CPA
Chief Communications Officer & Patient Advocate
Ms. Theresa McNeely

See Also

Discover More
What is the Intrinsic Value of one FIXX stock?

The intrinsic value of one FIXX stock under the Base Case scenario is 0.1693 USD.

Is FIXX stock undervalued or overvalued?

Compared to the current market price of 0.9347 USD, Homology Medicines Inc is Overvalued by 82%.